Augmented Zika and Dengue Neutralizing Antibodies Are Associated With Guillain-Barré Syndrome.
case_control · Level III
Where this comes from
- Record sourced from PubMed, PMID 30113672.
- Also identified by DOI 10.1093/infdis/jiy466 and PMC identifier 6284544.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The role of neutralizing antibodies in Zika-induced Guillain-Barré syndrome (GBS) has not yet been investigated. We conducted a case-control study using sera from the 2016 Zika epidemic in Colombia to determine the neutralizing antibody activity against Zika virus (ZIKV) and dengue virus serotype 2 (DENV2). We observed increased neutralizing antibody titers against DENV2 in ZIKV-infected individuals compared with uninfected controls and higher titers to both ZIKV and DENV2 in ZIKV-infected patients diagnosed with GBS compared with non-GBS ZIKV-infected controls. These data suggest that high neutralizing antibody titers to DENV and to ZIKV are associated with GBS during ZIKV infection.
Medical subject headings
- Antibodies, Neutralizing
- Antibodies, Viral
- Dengue
- Guillain-Barre Syndrome
- Zika Virus Infection